Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report

Vekić, Berislav; Dragojevic-Simic, Viktorija; Jakovljević, Mihajlo; Pilipović, Filip; Simić, Radoje; Zívić, R; Radovanovic, Dragce; Rančić, Nemanja

doi:10.3389/fphar.2019.00526

Cited by 8 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our earlier study, most of the expenses in the end-of-life stage results from inpatient care and administration of chemotherapy (11). In more recent study it was shown that the relative cost of medication was particularly high, accounting from 25.7% (2015) to 30.9% (2017) of total CRC costs in Serbia, while the cost of mAbs dominated other CRC-related expenses and accounted for 11.3, 12.2, 15.0, and 15.2% of all CRC-related expenses in 2014, 2015, 2016, and 2017, respectively (32). High costs associated with the treatment of metastatic CRC, including total drug expenditure was also reported in Croatia (38) and Turkey (39).…”

Section: Discussionmentioning

confidence: 99%

“…Total costs of diagnosis and treatment in the CRC patients are high throughout the world (32)(33)(34)(35) and very much depend on the initial TNM stage-the stage I disease is the least costly, whereas stage III is the most expensive due to the high cost of biological agents-monoclonal antibodies (mAbs) (12,36,37). In our earlier study, most of the expenses in the end-of-life stage results from inpatient care and administration of chemotherapy (11).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries

Vekić

Dragojevic-Simic

Jakovljević

et al. 2020

Front. Public Health

Self Cite

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most commonly diagnosed malignant neoplasms. The aim of the study was to evaluate and correlate most important epidemiological and economic indicators of CRC in 11 selected Balkan countries. The number of new CRC cases was 56,960, and the highest 5-year CRC prevalence was in Slovenia, Croatia, and Greece. Age-standardized CRC incidence rates were highest in Slovenia, Serbia, and Croatia, and age-standardized mortality rates were highest in Croatia, Serbia, and Bulgaria. Current Health Expenditure as % of Gross Domestic Product was the highest in Bosnia and Herzegovina and Serbia. The GDP per capita levels have shown positive correlation with the CRC incidence rate and prevalence. Absolute numbers of new and death-related CRC cases and 5-year prevalence in absolute numbers have shown strong positive correlation with GDP in million current US$. It has been shown that various economic indicators can be linked to the rate of incidence and prevalence of the CRC patients in the selected Balkan countries. Therefore, economic factors can influence the epidemiology of CRC, and heavy CRC burden in the Balkan region may be one of the indexes of the economic development.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries

Vekić

Dragojevic-Simic

Jakovljević

et al. 2020

Front. Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…In Serbia, CRC is the second most common carcinoma, as well as the second most common cause of cancer-related death, right after lung cancer in men, and breast cancer in women [14]. In addition to that fact, recent data show that the number of cases of CRC in Serbia was found to be on the 4% rise between the years 2014 and 2017 [15]. CRC is a very heterogeneous disease both in terms of its pathogenesis and in terms of molecular genetic characteristics [16].…”

Section: Discussionmentioning

confidence: 99%

Mutations in the KRAS gene as a predictive biomarker of therapeutic response in patients with colorectal cancer

Jugović

Nikolić

Madić

et al. 2021

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Introduction: Despite the important role of general KRAS mutational status in the selection of an adequate therapeutic protocol in patients with colorectal cancer (CRC), studies that focus on its specific mutations and their significance on progression of disease are scarce. This study aimed to determine the significance of specific KRAS mutations in response to standard chemotherapy protocols with oxaliplatin-based (FOLFOX 4, OXFL) in the first-line and irinotecan-based chemotherapy (FOLFIRI, IFL) in the second-line therapy, and to evaluate the correlation between these mutations and clinicopathological characteristics of CRC patients. Methods: Genomic DNA was extracted from the FFPE tumour tissue sections while the KRAS mutation test was performed by using PCR methods. Results: Prevalence of KRAS gene mutations in CRC patients was 45%. Mutated KRAS was more frequent in later stages of tumor infiltrations (P =0.0017), on the right side of the colon (P= 0.0044), and in patients who developed metastases in the first 6 months after CRC diagnosis than in patients who developed metastases after 24 months (P=0.0083). In a group of patients with a poor therapeutic response to standard chemotherapy the most frequent mutations in KRAS gene were G12D and G12V (63.88%), while in a group of patients with a good response to therapeutic protocols the most prevalent mutation was G12A (66.66%). Conclusion: Our results indicate that there was a significant difference in biological behaviour between tumours harboring different mutations in KRAS gene. Overall, mutation G12A could be a novel prognostic biomarker for CRC patients treated with standard chemotherapy.

show abstract

“…Although iPSC technology is rather costly [42], the use of iPSCs could lead to a significant reduction of medical costs for the treatment of many disorders, which are very important in medicine nowadays [43][44][45]. The iPSCs can provide guidance and assist healthcare decision planners and policymakers in allocating resources optimally.…”

Section: Therapeutic Potential and Barriers To The Safe Use Of Ipscmentioning

confidence: 99%

Induced pluripotent Stem Cells: Where we are currently?

Rančić¹,

Raščanin²,

Miljković³

et al. 2020

Halo 194

View full text Add to dashboard Cite

Induced Pluripotent Stem Cells (iPSCs) are a type of pluripotent stem cells generated by reprogramming an adult somatic cell genome to the stage of a pluripotent stem cell in vitro by inducing a forced expression of specific transcription factors that are important for the maintenance of pluripotency. The iPSCs seem to be very similar to Embryonic Stem Cells (ESCs) in terms of morphology, cell surface markers and gene expression levels, but recent studies have demonstrated some differences between the two cell types. However, iPSCs might have potential application in regenerative medicine, transplantation, drug testing, disease modelling, and avoidance of tissue rejection and with less ethical concern than ESCs. This paper aims to present the most important characteristics of iPSCs which have therapeutic significance.

show abstract

Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report

Cited by 8 publications

References 22 publications

A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries

A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries

Mutations in the KRAS gene as a predictive biomarker of therapeutic response in patients with colorectal cancer

Induced pluripotent Stem Cells: Where we are currently?

Contact Info

Product

Resources

About